Exploring immunotherapy in colorectal cancer
J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that
is thought to explain their exceptional responsiveness to immune checkpoint blockade …
is thought to explain their exceptional responsiveness to immune checkpoint blockade …
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
M Thibaudin, JD Fumet, B Chibaudel, J Bennouna… - Nature Medicine, 2023 - nature.com
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …
[HTML][HTML] Pembrolizumab in microsatellite-instability–high advanced colorectal cancer
T André, KK Shiu, TW Kim, BV Jensen… - … England Journal of …, 2020 - Mass Medical Soc
Abstract Background Programmed death 1 (PD-1) blockade has clinical benefit in
microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after …
microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after …
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
P Zhao, L Li, X Jiang, Q Li - Journal of hematology & oncology, 2019 - Springer
Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …
persistently popular topic in cancer research because they tremendously improve the …
[HTML][HTML] Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas
TA Knijnenburg, L Wang, MT Zimmermann… - Cell reports, 2018 - cell.com
DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic
response. We systematically analyzed somatic alterations to provide a comprehensive view …
response. We systematically analyzed somatic alterations to provide a comprehensive view …
[HTML][HTML] A compendium of mutational signatures of environmental agents
Summary Whole-genome-sequencing (WGS) of human tumors has revealed distinct
mutation patterns that hint at the causative origins of cancer. We examined mutational …
mutation patterns that hint at the causative origins of cancer. We examined mutational …
[HTML][HTML] Amelioration of oxidative stress, inflammation and tumor promotion by Tin oxide-Sodium alginate-Polyethylene glycol-Allyl isothiocyanate nanocomposites on …
W Wei, R Li, Q Liu, VD Seshadri… - Arabian Journal of …, 2021 - Elsevier
Background Colorectal cancer (CRC) is a frequently diagnosed cancer that primarily affects
the digestive system and an imperative cause of mortalities worldwide. Objective In this …
the digestive system and an imperative cause of mortalities worldwide. Objective In this …